# Cytokinetics (CYTK) — Analyst Forecast

CYTK · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/cytk/forecast

## Analyst consensus

| Consensus | Buy | Hold | Sell | Analysts |
| --- | --- | --- | --- | --- |
| Buy | 21 | 2 | 0 | 23 |

## Price target

| Low | Average | High | Analysts |
| --- | --- | --- | --- |
| $103.00 | $114.29 | $140.00 | 7 |

Last price $62.79 (as of Oct 13, 2026).

## Recent analyst ratings

| Date | Firm | Action | Rating | Price target |
| --- | --- | --- | --- | --- |
| Oct 8, 2026 | RBC Capital | Maintained | Outperform | $113.00 |
| Aug 31, 2026 | HC Wainwright & Co. | Maintained | Buy | $140.00 |
| Aug 13, 2026 | JP Morgan | Maintained | Overweight | $103.00 |
| Aug 13, 2026 | Barclays | Maintained | Overweight | $110.00 |
| Aug 10, 2026 | Truist Securities | Maintained | Buy | $112.00 |
| Aug 7, 2026 | Needham | Maintained | Buy | $112.00 |
| Aug 7, 2026 | Citizens | Maintained | Market Outperform | $110.00 |
| Aug 7, 2026 | RBC Capital | Maintained | Outperform | $112.00 |
| Jul 7, 2026 | RBC Capital | Maintained | Outperform | $117.00 |
| Jun 29, 2026 | UBS | Upgraded | Neutral → Buy | $115.00 |
| Jun 24, 2026 | Mizuho | Maintained | Outperform | $118.00 |
| Jun 17, 2026 | Needham | Maintained | Buy | $102.00 |
| May 19, 2026 | Citigroup | Initiated Coverage | Buy | $99.00 |
| May 12, 2026 | JP Morgan | Maintained | Overweight | $97.00 |
| May 11, 2026 | HC Wainwright & Co. | Maintained | Buy | $140.00 |
| May 7, 2026 | Wells Fargo | Maintained | Overweight | $105.00 |
| May 6, 2026 | RBC Capital | Maintained | Outperform | $119.00 |
| May 6, 2026 | Morgan Stanley | Maintained | Overweight | $103.00 |
| May 6, 2026 | Stifel | Maintained | Buy | $108.00 |
| May 5, 2026 | Needham | Maintained | Buy | $102.00 |

## Frequently Asked Questions

### What is the price target for CYTK stock?

The average 12-month analyst price target for Cytokinetics (CYTK) is $114.29, with a high estimate of $140.00 and a low of $103.00, across 7 analysts.

### Is CYTK a buy, sell, or hold?

Analysts covering Cytokinetics currently average a Buy rating: 21 buy, 2 hold and 0 sell, from 23 analysts. Ratings reflect analyst opinion, not investment advice.

### What upside do analysts see for CYTK?

The average price target of $114.29 implies 82.01% upside from the last price of $62.79.

### What is the latest analyst rating on CYTK?

On Oct 8, 2026, RBC Capital maintained Cytokinetics at Outperform with a price target of $113.00.

---

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).